Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Integrin-Mediated TGFβ Activation Modulates the Tumour Microenvironment.

Brown NF, Marshall JF.

Cancers (Basel). 2019 Aug 21;11(9). pii: E1221. doi: 10.3390/cancers11091221. Review.

2.

Salmonella Effectors SseK1 and SseK3 Target Death Domain Proteins in the TNF and TRAIL Signaling Pathways.

Newson JPM, Scott NE, Yeuk Wah Chung I, Wong Fok Lung T, Giogha C, Gan J, Wang N, Strugnell RA, Brown NF, Cygler M, Pearson JS, Hartland EL.

Mol Cell Proteomics. 2019 Jun;18(6):1138-1156. doi: 10.1074/mcp.RA118.001093. Epub 2019 Mar 22.

PMID:
30902834
3.

Inhibitors of Aldosterone Synthase.

Weldon SM, Brown NF.

Vitam Horm. 2019;109:211-239. doi: 10.1016/bs.vh.2018.10.002. Epub 2018 Dec 21. Review.

PMID:
30678857
4.

Harnessing the immune system in glioblastoma.

Brown NF, Carter TJ, Ottaviani D, Mulholland P.

Br J Cancer. 2018 Nov;119(10):1171-1181. doi: 10.1038/s41416-018-0258-8. Epub 2018 Nov 5. Review.

5.

Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study.

Dillon MT, Grove L, Newbold KL, Shaw H, Brown NF, Mendell J, Chen S, Beckman RA, Jennings A, Ricamara M, Greenberg J, Forster M, Harrington KJ.

Clin Cancer Res. 2019 Jan 15;25(2):487-495. doi: 10.1158/1078-0432.CCR-18-1539. Epub 2018 Oct 16.

PMID:
30327312
6.

A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098.

Brown NF, Williams M, Arkenau HT, Fleming RA, Tolson J, Yan L, Zhang J, Swartz L, Singh R, Auger KR, Lenox L, Cox D, Lewis Y, Plisson C, Searle G, Saleem A, Blagden S, Mulholland P.

Neuro Oncol. 2018 Nov 12;20(12):1634-1642. doi: 10.1093/neuonc/noy078.

PMID:
29788497
7.

Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activity.

Meyers K, Cogan DA, Burke J, Arenas R, Balestra M, Brown NF, Chen Z, Cerny MA, Clifford HE, Colombo F, Fader L, Frederick KS, Guo X, Goldberg D, Hornberger KR, Kugler S, Lord J, Marshall DR, Moss N, Parmentier JH, Richman JR, Schmenk J, Weldon SM, Yu M, Zhang M.

Bioorg Med Chem Lett. 2018 Mar 1;28(5):979-984. doi: 10.1016/j.bmcl.2017.12.015. Epub 2017 Dec 8.

PMID:
29254646
8.

Dabrafenib and trametinib in BRAFV600E mutated glioma.

Brown NF, Carter T, Kitchen N, Mulholland P.

CNS Oncol. 2017 Oct;6(4):291-296. doi: 10.2217/cns-2017-0006. Epub 2017 Oct 6.

9.

Impact of Aldosterone Synthase Inhibitor FAD286 on Steroid Hormone Profile in Human Adrenocortical Cells.

Brunssen C, Hofmann A, Peitzsch M, Frenzel A, Ziegler CG, Brown NF, Weldon SM, Eisenhofer G, Willenberg HS, Bornstein SR, Morawietz H.

Horm Metab Res. 2017 Sep;49(9):701-706. doi: 10.1055/s-0043-113829. Epub 2017 Jul 31.

PMID:
28759940
10.

The Aldosterone Synthase Inhibitor FAD286 is Suitable for Lowering Aldosterone Levels in ZDF Rats but not in db/db Mice.

Hofmann A, Brunssen C, Peitzsch M, Balyura M, Mittag J, Frenzel A, Jannasch A, Brown NF, Weldon SM, Gueneva-Boucheva KK, Eisenhofer G, Bornstein SR, Morawietz H.

Horm Metab Res. 2017 Jun;49(6):466-471. doi: 10.1055/s-0043-101821. Epub 2017 Apr 20.

PMID:
28427090
11.

Interactome disassembly during apoptosis occurs independent of caspase cleavage.

Scott NE, Rogers LD, Prudova A, Brown NF, Fortelny N, Overall CM, Foster LJ.

Mol Syst Biol. 2017 Jan 12;13(1):906. doi: 10.15252/msb.20167067.

12.

Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.

Brown NF, Carter T, Mulholland P.

CNS Oncol. 2017 Jan;6(1):5-9. doi: 10.2217/cns-2016-0031. Epub 2016 Oct 26.

13.

Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats.

Hofmann A, Brunssen C, Peitzsch M, Martin M, Mittag J, Jannasch A, Engelmann F, Brown NF, Weldon SM, Huber J, Streicher R, Deussen A, Eisenhofer G, Bornstein SR, Morawietz H.

Endocrinology. 2016 Oct;157(10):3844-3855. Epub 2016 Aug 15.

PMID:
27526033
14.

Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman Primates.

Weldon SM, Cerny MA, Gueneva-Boucheva K, Cogan D, Guo X, Moss N, Parmentier JH, Richman JR, Reinhart GA, Brown NF.

J Pharmacol Exp Ther. 2016 Oct;359(1):142-50. doi: 10.1124/jpet.116.236463. Epub 2016 Aug 1.

PMID:
27481775
15.

SseK3 Is a Salmonella Effector That Binds TRIM32 and Modulates the Host's NF-κB Signalling Activity.

Yang Z, Soderholm A, Lung TW, Giogha C, Hill MM, Brown NF, Hartland E, Teasdale RD.

PLoS One. 2015 Sep 22;10(9):e0138529. doi: 10.1371/journal.pone.0138529. eCollection 2015.

16.

A horizontally acquired transcription factor coordinates Salmonella adaptations to host microenvironments.

Brown NF, Rogers LD, Sanderson KL, Gouw JW, Hartland EL, Foster LJ.

MBio. 2014 Sep 23;5(5):e01727-14. doi: 10.1128/mBio.01727-14.

17.

The Salmonella type III effector SspH2 specifically exploits the NLR co-chaperone activity of SGT1 to subvert immunity.

Bhavsar AP, Brown NF, Stoepel J, Wiermer M, Martin DD, Hsu KJ, Imami K, Ross CJ, Hayden MR, Foster LJ, Li X, Hieter P, Finlay BB.

PLoS Pathog. 2013;9(7):e1003518. doi: 10.1371/journal.ppat.1003518. Epub 2013 Jul 25.

18.

Global impact of Salmonella pathogenicity island 2-secreted effectors on the host phosphoproteome.

Imami K, Bhavsar AP, Yu H, Brown NF, Rogers LD, Finlay BB, Foster LJ.

Mol Cell Proteomics. 2013 Jun;12(6):1632-43. doi: 10.1074/mcp.M112.026161. Epub 2013 Mar 3.

19.

Identification of an Adamantyl Azaquinolone JNK Selective Inhibitor.

Haynes NE, Scott NR, Chen LC, Janson CA, Li JK, Lukacs CM, Railkar A, Tozzo E, Whittard T, Brown NF, Cheung AW.

ACS Med Chem Lett. 2012 Aug 8;3(9):764-8. doi: 10.1021/ml300175c. eCollection 2012 Sep 13.

20.

Managing heparin infusions.

Brown NF, Bart-Smith E, Gillett D.

Br J Hosp Med (Lond). 2012 Jun;73(6):C85-8. No abstract available.

PMID:
22875274
21.

Splenomegaly.

Brown NF, Marks DJ, Smith PJ, Bloom SL.

Br J Hosp Med (Lond). 2011 Nov;72(11):M166-9. Review.

PMID:
22082977
22.

Potential origins and horizontal transfer of type III secretion systems and effectors.

Brown NF, Finlay BB.

Mob Genet Elements. 2011 Jul;1(2):118-121. Epub 2011 Jul 1.

23.

Phosphoproteomic analysis of Salmonella-infected cells identifies key kinase regulators and SopB-dependent host phosphorylation events.

Rogers LD, Brown NF, Fang Y, Pelech S, Foster LJ.

Sci Signal. 2011 Sep 20;4(191):rs9. doi: 10.1126/scisignal.2001668.

24.

Salmonella phage ST64B encodes a member of the SseK/NleB effector family.

Brown NF, Coombes BK, Bishop JL, Wickham ME, Lowden MJ, Gal-Mor O, Goode DL, Boyle EC, Sanderson KL, Finlay BB.

PLoS One. 2011 Mar 18;6(3):e17824. doi: 10.1371/journal.pone.0017824.

25.

Inhibition of the PtdIns(5) kinase PIKfyve disrupts intracellular replication of Salmonella.

Kerr MC, Wang JT, Castro NA, Hamilton NA, Town L, Brown DL, Meunier FA, Brown NF, Stow JL, Teasdale RD.

EMBO J. 2010 Apr 21;29(8):1331-47. doi: 10.1038/emboj.2010.28. Epub 2010 Mar 18.

26.

Nramp1 expression by dendritic cells modulates inflammatory responses during Salmonella Typhimurium infection.

Valdez Y, Diehl GE, Vallance BA, Grassl GA, Guttman JA, Brown NF, Rosenberger CM, Littman DR, Gros P, Finlay BB.

Cell Microbiol. 2008 Aug;10(8):1646-61. doi: 10.1111/j.1462-5822.2008.01155.x. Epub 2008 Apr 7.

27.

Hepatocyte growth factor is a novel stimulator of glucose uptake and metabolism in skeletal muscle cells.

Perdomo G, Martinez-Brocca MA, Bhatt BA, Brown NF, O'Doherty RM, Garcia-Ocaña A.

J Biol Chem. 2008 May 16;283(20):13700-6. doi: 10.1074/jbc.M707551200. Epub 2008 Mar 24.

28.

A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels.

Stefanovic-Racic M, Perdomo G, Mantell BS, Sipula IJ, Brown NF, O'Doherty RM.

Am J Physiol Endocrinol Metab. 2008 May;294(5):E969-77. doi: 10.1152/ajpendo.00497.2007. Epub 2008 Mar 18.

29.

The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes.

Brown NF, Stefanovic-Racic M, Sipula IJ, Perdomo G.

Metabolism. 2007 Nov;56(11):1500-7.

PMID:
17950100
30.

Src homology domain 2 adaptors affect adherence of Salmonella enterica serovar Typhimurium to non-phagocytic cells.

Boyle EC, Brown NF, Brumell JH, Finlay BB.

Microbiology. 2007 Oct;153(Pt 10):3517-26.

PMID:
17906149
31.

SopD acts cooperatively with SopB during Salmonella enterica serovar Typhimurium invasion.

Bakowski MA, Cirulis JT, Brown NF, Finlay BB, Brumell JH.

Cell Microbiol. 2007 Dec;9(12):2839-55. Epub 2007 Aug 13.

PMID:
17696999
32.

Oral infection of mice with Salmonella enterica serovar Typhimurium causes meningitis and infection of the brain.

Wickham ME, Brown NF, Provias J, Finlay BB, Coombes BK.

BMC Infect Dis. 2007 Jun 27;7:65.

33.

Virulence is positively selected by transmission success between mammalian hosts.

Wickham ME, Brown NF, Boyle EC, Coombes BK, Finlay BB.

Curr Biol. 2007 May 1;17(9):783-8. Epub 2007 Apr 19.

34.

SseL is a salmonella-specific translocated effector integrated into the SsrB-controlled salmonella pathogenicity island 2 type III secretion system.

Coombes BK, Lowden MJ, Bishop JL, Wickham ME, Brown NF, Duong N, Osborne S, Gal-Mor O, Finlay BB.

Infect Immun. 2007 Feb;75(2):574-80. Epub 2006 Dec 11.

36.

Bacterial genetic determinants of non-O157 STEC outbreaks and hemolytic-uremic syndrome after infection.

Wickham ME, Lupp C, Mascarenhas M, Vazquez A, Coombes BK, Brown NF, Coburn BA, Deng W, Puente JL, Karmali MA, Finlay BB.

J Infect Dis. 2006 Sep 15;194(6):819-27. Epub 2006 Aug 11.

PMID:
16941350
37.

Salmonella enterica serovar Typhimurium effectors SopB, SopE, SopE2 and SipA disrupt tight junction structure and function.

Boyle EC, Brown NF, Finlay BB.

Cell Microbiol. 2006 Dec;8(12):1946-57. Epub 2006 Jul 26.

PMID:
16869830
38.

Mutational analysis of Salmonella translocated effector members SifA and SopD2 reveals domains implicated in translocation, subcellular localization and function.

Brown NF, Szeto J, Jiang X, Coombes BK, Finlay BB, Brumell JH.

Microbiology. 2006 Aug;152(Pt 8):2323-43.

PMID:
16849798
39.

Crossing the line: selection and evolution of virulence traits.

Brown NF, Wickham ME, Coombes BK, Finlay BB.

PLoS Pathog. 2006 May;2(5):e42. Review.

40.

Salmonella pathogenicity island 2 is expressed prior to penetrating the intestine.

Brown NF, Vallance BA, Coombes BK, Valdez Y, Coburn BA, Finlay BB.

PLoS Pathog. 2005 Nov;1(3):e32. Epub 2005 Nov 18.

41.

Negative regulation of Salmonella pathogenicity island 2 is required for contextual control of virulence during typhoid.

Coombes BK, Wickham ME, Lowden MJ, Brown NF, Finlay BB.

Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17460-5. Epub 2005 Nov 21.

42.

Skeletal muscle lipid and its association with insulin resistance: what is the role for exercise?

Goodpaster BH, Brown NF.

Exerc Sport Sci Rev. 2005 Jul;33(3):150-4. Review.

PMID:
16006823
43.

Genetic and molecular analysis of GogB, a phage-encoded type III-secreted substrate in Salmonella enterica serovar typhimurium with autonomous expression from its associated phage.

Coombes BK, Wickham ME, Brown NF, Lemire S, Bossi L, Hsiao WW, Brinkman FS, Finlay BB.

J Mol Biol. 2005 May 13;348(4):817-30.

PMID:
15843015
44.

A type IV pilin, PilA, Contributes To Adherence of Burkholderia pseudomallei and virulence in vivo.

Essex-Lopresti AE, Boddey JA, Thomas R, Smith MP, Hartley MG, Atkins T, Brown NF, Tsang CH, Peak IR, Hill J, Beacham IR, Titball RW.

Infect Immun. 2005 Feb;73(2):1260-4.

45.

The related effector proteins SopD and SopD2 from Salmonella enterica serovar Typhimurium contribute to virulence during systemic infection of mice.

Jiang X, Rossanese OW, Brown NF, Kujat-Choy S, Galán JE, Finlay BB, Brumell JH.

Mol Microbiol. 2004 Dec;54(5):1186-98.

46.
47.

Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei.

Holden MT, Titball RW, Peacock SJ, Cerdeño-Tárraga AM, Atkins T, Crossman LC, Pitt T, Churcher C, Mungall K, Bentley SD, Sebaihia M, Thomson NR, Bason N, Beacham IR, Brooks K, Brown KA, Brown NF, Challis GL, Cherevach I, Chillingworth T, Cronin A, Crossett B, Davis P, DeShazer D, Feltwell T, Fraser A, Hance Z, Hauser H, Holroyd S, Jagels K, Keith KE, Maddison M, Moule S, Price C, Quail MA, Rabbinowitsch E, Rutherford K, Sanders M, Simmonds M, Songsivilai S, Stevens K, Tumapa S, Vesaratchavest M, Whitehead S, Yeats C, Barrell BG, Oyston PC, Parkhill J.

Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14240-5. Epub 2004 Sep 17.

48.

Identification of a novel two-partner secretion system from Burkholderia pseudomallei.

Brown NF, Logue CA, Boddey JA, Scott R, Hirst RG, Beacham IR.

Mol Genet Genomics. 2004 Sep;272(2):204-15. Epub 2004 Aug 13.

PMID:
15316770
49.

Fatty acid-induced insulin resistance in L6 myotubes is prevented by inhibition of activation and nuclear localization of nuclear factor kappa B.

Sinha S, Perdomo G, Brown NF, O'Doherty RM.

J Biol Chem. 2004 Oct 1;279(40):41294-301. Epub 2004 Jul 12.

50.

Searching for virulence Burkholderia pseudomallei genes by immunoscreening the lambda ZAPII expressed genomic library.

Jitsurong S, Chirathaworn C, Brown NF, Beacham IR, Tumwasorn S.

Southeast Asian J Trop Med Public Health. 2003 Dec;34(4):810-21.

PMID:
15115093

Supplemental Content

Loading ...
Support Center